BioSpace News Archive

Haemonetics Corporation announced that financial results for its first quarter fiscal 2023, which ended July 2, 2022, are available on its Investor Relations website.

Emergent BioSolutions Inc. announced that members of the company’s executive management team will participate in the following investor conferences.

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company with a Research & Development innovation engine that aims to discover, develop, and ultimately deliver impactful medicines to patients, reported financial results and business highlights for the second quarter ended June 30, 2022, and provided a program update for ZF874 for Alpha-1 Antitrypsin Deficiency.

In situ hybridization refers to a well-established set of methods for the visualization and detection of specific nucleic acid sequences in whole organisms, cytological preparations, and tissue sections.

Diffuse large B-Cell Lymphoma is seeing a rise in its incidence worldwide. As per U.K. Lyphoma Association, Britain lone sees about 4800 cases of this every year.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global dental 3D printing market is expected to witness a 2.6X growth over the forecast period.

The mounting cases of people suffering from respiratory disorders is the foremost factor driving the global respiratory diagnostics market.

Hansa Biopharma AB, ‘Hansa’, pioneer in enzyme technology for rare immunological conditions, welcomes the publication in Transplant International, the official journal of ESOT, of ESOT’s guidelines for desensitization treatment of highly sensitized kidney transplant patients.1

Artios Pharma Limited announces it has initiated a Phase 2 study with ART4215, a small molecule inhibitor of polymerase theta in combination with talazoparib, an oral poly polymerase inhibitor in an expansion study for the treatment of BRCA deficient breast cancer.

Australian biotechnology company Starpharma announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA.